|
LYSMD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66167080095647E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.13353770814228E-13 |
| Normal-vs-Stage2 |
1.10123021812569E-12 |
| Normal-vs-Stage3 |
1.6286971771251E-12 |
| Normal-vs-Stage4 |
1.6251444634463E-12 |
| Stage1-vs-Stage2 |
8.035800E-01 |
| Stage1-vs-Stage3 |
6.324400E-02 |
| Stage1-vs-Stage4 |
1.273580E-02 |
| Stage2-vs-Stage3 |
1.404210E-01 |
| Stage2-vs-Stage4 |
2.949900E-02 |
| Stage3-vs-Stage4 |
3.281400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63857816204427E-12 |
| Normal-vs-AfricanAmerican |
2.23749999972433E-07 |
| Normal-vs-Asian |
1.89215310086865E-12 |
| Caucasian-vs-AfricanAmerican |
2.988400E-01 |
| Caucasian-vs-Asian |
6.090200E-01 |
| AfricanAmerican-vs-Asian |
4.633200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62847513252018E-12 |
| Normal-vs-Female |
1.70818914568827E-12 |
| Male-vs-Female |
5.977900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.8686163727466E-12 |
| Normal-vs-Age(41-60Yrs) |
1.63569158218024E-12 |
| Normal-vs-Age(61-80Yrs) |
8.77076189453874E-15 |
| Normal-vs-Age(81-100Yrs) |
2.103900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.951800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.118500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.972000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.127800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.567760E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.472840E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.998700E-04 |
| Classical-VS-Follicular |
3.523800E-01 |
| Classical-VS-Other |
2.695400E-01 |
| Classical-VS-Normal |
1.93478566501426E-12 |
| Tall-VS-Follicular |
3.041500E-04 |
| Tall-VS-Other |
7.219600E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
2.052000E-01 |
| Follicular-VS-Normal |
3.45479200802856E-12 |
| Other-VS-Normal |
2.44730000042992E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66089364483923E-12 |
| Normal-vs-N1 |
1.62525548574877E-12 |
| N0-vs-N1 |
7.767700E-02 |
|
|
